# Morgan Stanley | RESEARCH

November 10, 2025 03:44 PM GMT

# **US Economics** | North America

# More data, less fog: Our expectations for data releases post-shutdown

Recent developments mean the government shutdown could end this week. We lay out our expectations for when data should be released. We think the data in-hand by the time of the December Fed meeting will be enough for them to cut.

# Key Takeaways

- The first major data print post-shutdown will likely be the September employment report. Other data on inflation and spending will probably take 1-2 weeks.
- The Fed will have most September data but limited Q4 data in time for the meeting. It is possible they have October and/or November payrolls in time.
- We expect the unemployment rate to rise through year-end, and we expect weaker spending growth in Q4.
- We continue to expect the Fed to cut by 25bp in December. With the return to data dependency, stronger labor market data than expected is a risk to this view.

**Exhibit 1:** Estimated release dates for data based on 2013 shutdown, if shutdown ends Friday, Nov 14th

Data	# of business days after 2013 shutdown end that data were released	Implied new release date if shutdown ends Friday, Nov 14th 19-Nov-25		
Aug Construction spending	3			
Sept Employment situation	3	19-Nov-25		
Sept Import/Export prices	4	20-Nov-25		
Aug Trade balance	5	21-Nov-25		
Sept Industrial production	7	25-Nov-25		
Sept Retail sales	8	26-Nov-25		
Sept PPI	8	26-Nov-25		
Q3 GDP	15	5-Dec-25		
Sept Personal income and outlays	16	8-Dec-25		
Oct Employment situation	16	8-Dec-25		
Q3 ECI	16	8-Dec-25		
	December FOMC Meeting: Dec 9-10th			
Sept Trade balance	20	12-Dec-25		
Oct Import/Export prices	21	15-Dec-25		
Oct Industrial production	21	15-Dec-25		
Oct Retail sales	24	18-Dec-25		
Oct CPI	24	18-Dec-25		
Oct PPI	25	19-Dec-25		
Sept Construction spending	32	30-Dec-25		
Sept New home sales	34	1-Jan-26		
Oct New home sales	34	1-Jan-26		
Oct Personal income and outlays	36	5-Jan-26		
Sept Housing starts	44	15-Jan-26		
Oct Housing starts	44	15-Jan-26		

Note: Color coding implies likeliness of data by the time of the December Fed meeting. Source: Morgan Stanley Research, BLS, BEA, Bloomberg, Census Bureau, Federal Reserve



MORGAN STANLEY & CO. LLC

### Michael T Gapen

Chief US Economist

Michael.Gapen@morganstanley.com +1 212 761-0571

# Heather Berger

Economis

Heather.Berger@morganstanley.com +1 212 761-2296

### Sam D Coffin

Economist

Sam.Coffin@morganstanley.com +1 212 761-4630

### Ariana Salvatore

Strategi

Ariana.Salvatore@morganstanley.com

# Diego Anzoategui

conomis

Diego.Anzoategui@morganstanley.com +1 212 761-8573

### Arunima Sinha

Global Economist

Arunima.Sinha@morganstanley.com +1 212 761-4125

# Lingdi Xu

Lingdi.Xu@morganstanley.com +1 212 761-2957

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

# Expectations for data releases post-shutdown

Given recent developments, it is looking likely that the government shutdown will end this week. The Senate has agreed to move forward on a clean CR (keeping the government funded until January), with the House set to follow suit later this week (reporting indicates a vote is possible mid to later this week). The vote is contingent upon a future vote on the ACA subsidy extension, which we expect Republicans at that later date will remain opposed to, per leadership statements. The continuing resolution under discussion keeps funding levels flat through Jan 30 of next year, at which point Congress will need to pass either another CR or the annual appropriations bills.

The important questions now are: when will data be released, and will the data point to another 25bp cut in December? We expect incoming employment reports to show continued weakness in labor demand, which we think will be enough for the Fed to cut in December. Stronger data than we expect, especially given the potential lack of Q4 data in time for the meeting, is a risk to this view.

# Timing of data releases

In Exhibit 2 below, we show how long it took for data to be released after the 2013 shutdown. Using these timelines, we estimate the timing of data releases if the shutdown were to end Friday, Nov 14th. If the shutdown ends Thursday, we could expect the data one business day earlier than noted in the table, and so forth.

The first major data print we expect is September payrolls, around 3 business days after the end of the shutdown. These data were already fully collected before the shutdown began and should be released relatively quickly. We expect payrolls rose 50k in September and the unemployment rate was unchanged at 4.3%. See here for more details on our expectations for the print.

Most other major data prints for September will probably take a week or two to be released. In the 2013 shutdown, September retail sales and September PPI were not released until 8 and 9 business days after the end of the shutdown. If we assume the same timeline, we should expect these right before Thanksgiving.

October data will take longer as data collections were delayed. The 2013 timeline implies we will not have spending or inflation data past September in time for the Fed meeting. This year's shutdown lasted the whole month of October, as opposed to the 2013 shutdown which ended in mid-October. As a result, October data may take even longer than our estimates. Still, if we use the 2013 shutdown timing, we would not get October retail sales and inflation data until around December 18, after the Fed meeting. October data quality could be affected: Employment and retail sales data should be as reliable as they ever are. However, CPI data quality worsens.

October and November payrolls could come in time for the December Fed meeting. The 2013 timeline implies October payrolls will be released the Monday of the week of the Fed meeting. If the shutdown ends this week, we also think it is possible that November payrolls could be released on time or close to it, which could be before the meeting.

**Putting it altogether:** By the time of the meeting we expect the Fed will have September payrolls, September inflation (and at least the Fed's internal estimate of PCE prices), and September retail sales, in addition to some data on trade and manufacturing. It is also *possible* they have October and November employment, September personal income, outlays, and PCE prices, and the advance release of Q3 GDP.

**Exhibit 2:** Estimated release dates for data based on 2013 shutdown, if shutdown ends Friday, Nov 14th

Data	# of business days after 2013 shutdown end that data were released	Implied new release date if shutdown ends Friday, Nov 14th			
Aug Construction spending	3	19-Nov-25			
Sept Employment situation	3	19-Nov-25			
Sept Import/Export prices	4	20-Nov-25			
Aug Trade balance	5	21-Nov-25			
Sept Industrial production	7	25-Nov-25			
Sept Retail sales	8	26-Nov-25			
Sept PPI	8	26-Nov-25			
Q3 GDP	15	5-Dec-25			
Sept Personal income and outlays	16	8-Dec-25			
Oct Employment situation	16	8-Dec-25			
Q3 ECI	16	8-Dec-25			
	December FOMC Meeting: Dec 9-10th				
Sept Trade balance	20	12-Dec-25			
Oct Import/Export prices	21	15-Dec-25			
Oct Industrial production	21	15-Dec-25			
Oct Retail sales	24	18-Dec-25			
Oct CPI	24	18-Dec-25			
Oct PPI	25	19-Dec-25			
Sept Construction spending	32	30-Dec-25			
Sept New home sales	34	1-Jan-26			
Oct New home sales	34	1-Jan-26			
Oct Personal income and outlays	36	5-Jan-26			
Sept Housing starts	44	15-Jan-26			
Oct Housing starts	44	15-Jan-26			

Note: Color coding implies likeliness of data by the time of the December Fed meeting. Source: Morgan Stanley Research, BLS, BEA, Bloomberg. Census Bureau. Federal Reserve

# Implications for the Fed: Let the data speak

Our base case remains that these data will be enough for the Fed to cut 25bp at the December meeting. The key to continued cuts, in our view, is weakness in labor demand and a drift higher in the unemployment rate. Our expectation of September payrolls at 50k would not show new weakness, but it would show continued slow labor demand. If we do get the October and/or November employment reports in time for the meeting, we expect the unemployment rate to drift higher. We forecast the unemployment rate at 4.3% in September, 4.5% in October, and 4.5% in November. Part of the rise in October is due to furloughed employees from the shutdown, and to a lesser extent federal employees who took buyout agreements earlier this year. Even if these data are not released in time for the meeting, claims and private sources of labor data could show the same trends. A further rise in continuing claims would suggest slower hiring.

We do not expect the Fed to have data on fourth quarter personal spending in time for the meeting (aside from car sales), but we think private data will point to weakness. We expect slower real income growth to weigh on spending in Q4. Even if the data are not released in time for the meeting, headlines and initial data around Black Friday sales and holiday spending could show weakness.

That said, our expectations for continued cuts from the Fed is based primarily on the evolution of labor market data, which we expect will show modestly increased slack and still-present downside risk to employment.

**Stronger data than we expect is a risk to our call for a December cut.** At the October FOMC meeting, Chair Powell said that rate cuts in December were not a "done deal" and

"far from it." He said there was strong division within the committee about the outlook for rates in December and communicated that the committee would be more data dependent in its determination than in September and October when moves were more oriented to risk management decisions.

With the renewed focus on data rather than risk management, stronger data could mean the Fed pauses in December. Stronger data could include a decline in the unemployment rate in September or no further rise in October, if we have those data in time. It could also be reflected through an acceleration in nonfarm payrolls that could lead the committee to conclude the soft patch in hiring from May to August was in the rear-view mirror.

We will also be paying attention to revisions to the employment report. We find evidence that indicates revisions to payrolls tend to be in the positive direction in Q4, in contrast to downward revisions earlier in the year.

Holiday spending could also come in stronger than expected, and especially if we do not have October payrolls in time for the meeting, this could ease fears of a weaker labor market and consumer. While our base case remains that the Fed will cut in December, January, April, and July, the risks are skewed toward fewer cuts.

In sum, risks to markets are asymmetric. Markets are expecting cuts, so data that validates this should not significantly move markets unless they point to a sharp increase in layoffs. The real risk is the labor market data re-accelerates to match the activity data. In that case, markets would be forced to rethink the policy rate path.



# **Disclosure Section**

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

# **Analyst Certification**

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Ariana Salvatore.

# **Global Research Conflict Management Policy**

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

# **Important Regulatory Disclosures on Subject Companies**

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

# **STOCK RATINGS**

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

# **Global Stock Ratings Distribution**

(as of October 31, 2025)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
Stock Rating Category	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1501	41%	384	46%	26%	703	41%
Equal-weight/Hold	1609	44%	370	44%	23%	788	46%
Not-Rated/Hold	4	0%	1	0%	25%	1	0%
Underweight/Sell	568	15%	80	10%	14%	223	13%
Total	3,682		835			1715	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

### **Analyst Stock Ratings**

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over

MORGAN STANLEY RESEARCH



the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

# **Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

# Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

# **Other Important Disclosures**

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms\_and\_conditions.pdf) and the following link to review the audit report (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Research\_Audit\_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell on the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.



With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (\*MSTL\*). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118)); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

MORGAN STANLEY RESEARCH 7



Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

The following authors are Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity securities: Ariana Salvatore.

The following authors are neither Equity Research Analysts/Strategists nor Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity or fixed income securities: Michael T Gapen; Lingdi Xu; Heather Berger; Arunima Sinha; Diego Anzoategui; Sam D Coffin.

© 2025 Morgan Stanley